

200 Park Ave. S. Suite 1501
New York, NY 10003
Ph: +1 866 966 4483
+1 212 461 3692
Fax: +1 212 780 0607



2010 SCIENTIFIC STRATEGIC PLAN OF THE GLOBAL HIV VACCINE ENTERPRISE: AN OPPORTUNITY FOR FEEDBACK AND INPUT

In response to significant progress in the field of HIV vaccine research over the past five years, the Global HIV Vaccine Enterprise is currently developing the 2010 Enterprise Scientific Strategic Plan. This is an inclusive, compelling plan that will reflect the views of the world's leading scientists and the perspectives of major, global stakeholders engaged in HIV vaccine research and development. The Plan will include key, current scientific questions for consideration, a delineation of structural, organizational and capacity-building approaches, recommendations for funding, and milestones to measure success.

We are consulting with the general HIV research community about the challenges and opportunities facing the field to help inform the development of the 2010 Plan. Our first consultation took place on July 19, 2009 at the IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town, South Africa. In this second consultation at the AIDS Vaccine 2009 conference, we will request input on specific priorities, goals and recommendations presented by five different Scientific Strategic Plan Working Groups. The Working Groups are:

- Immunogens and Antigen Processing
- Host Genetics and HIV Diversity
- Novel Approaches, including Systems Biology, to HIV Vaccine Research and Development
- Bridging the Gaps between Fundamental, Preclinical, and Clinical Research
- Young and Early Career Investigators

In addition, we will discuss the broad issues that surround the science, but are not directly scientific in nature (e.g. ethics, regulatory issues, broader prevention issues, maintaining trial site capacity).

This consultation will feature a panel discussion of the Chairs of the above listed Working Groups (see http://www.hivvaccineenterprise.org/updated_plan/overview.aspx for more information on the Working Groups and their Chairs). The discussion will be co-moderated by Alan Bernstein, Executive Director of the Global HIV Vaccine Enterprise and Mitchell Warren, Executive Director of AVAC and an Enterprise Council member.

For more information on the Global HIV Vaccine Enterprise and the Scientific Strategic Plan, please visit http://www.hivvaccineenterprise.org/updated_plan/overview.aspx or send an email message to ssp@vaccineenterprise.org.